StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) income statement

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Interpace Biosciences, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
63.7%
Operating margin
11.5%
Net margin
67.6%
Return on equity, FY2025
244.0%

Financial strength

Current ratio
2.22
Debt to equity
–
Debt to assets
–
Cash to current liabilities
54.3%

Valuation

P/E ratio
5.6
Price to sales
3.83
Price to book
5.96
Dividend yield
–

See a number that looks wrong?